An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Hypha Labs, Inc. (OTC PINK:DIGP) changes its name from Digipath, Inc. to focus on producing active ingredients from functional mushrooms like psilocybin using innovative bioreactor technology. The company aims to offer pure, consistent, and measurable doses of these ingredients for consumer and commercial use. With a subscription-based model, Hypha Labs plans to revolutionize the production of functional mushrooms, tapping into the growing market for psychedelic and functional mushrooms as potential treatments for various health conditions.
Hypha Labs, Inc. (OTC PINK:DIGP) ha cambiato il suo nome da Digipath, Inc. con l'obiettivo di concentrarsi sulla produzione di ingredienti attivi derivati da funghi funzionali come la psilocibina, utilizzando una tecnologia bioreattiva innovativa. La compagnia mira a offrire dosi pure, consistenti e misurabili di questi ingredienti per l'uso sia personale che commerciale. Con un modello basato su abbonamento, Hypha Labs prevede di rivoluzionare la produzione di funghi funzionali, sfruttando il crescente mercato dei funghi psichedelici e funzionali come potenziali trattamenti per diverse condizioni di salute.
Hypha Labs, Inc. (OTC PINK:DIGP) ha cambiado su nombre de Digipath, Inc. para enfocarse en la producción de ingredientes activos de hongos funcionales como la psilocibina mediante tecnología innovadora de biorreactores. La empresa tiene como objetivo ofrecer dosis puras, consistentes y medibles de estos ingredientes para uso tanto consumer como comercial. Con un modelo de suscripción, Hypha Labs planea revolucionar la producción de hongos funcionales, aprovechando el creciente mercado de hongos psicodélicos y funcionales como tratamientos potenciales para varias condiciones de salud.
Hypha Labs, Inc. (OTC PINK:DIGP)은 Digipath, Inc.에서 이름을 변경하여 기능성 버섯의 활성 성분을 생산하는 것에 집중하려고 합니다. 이를 위해 혁신적인 바이오리액터 기술을 사용하여 실로시빈과 같은 성분을 생산할 예정입니다. 회사는 이러한 재료를 소비자 및 상업용도로 순수하고 일관되며 측정 가능한 용량을 제공하고자 합니다. 구독 기반 모델로, Hypha Labs는 기능성 버섯 생산을 혁명적으로 바꾸고 여러 건강 상태에 대한 잠재적 치료제로서 심리적 및 기능적 버섯 시장을 이용할 계획입니다.
Hypha Labs, Inc. (OTC PINK:DIGP) a changé son nom de Digipath, Inc. afin de se concentrer sur la production d'ingrédients actifs issus de champignons fonctionnels tels que la psilocybine en utilisant une technologie de bioréacteur innovante. La société vise à offrir des doses pures, cohérentes et mesurables de ces ingrédients pour une utilisation par les consommateurs et les professionnels. Avec un modèle basé sur l'abonnement, Hypha Labs envisage de révolutionner la production de champignons fonctionnels, en exploitant le marché en croissance des champignons psychédéliques et fonctionnels comme traitements potentiels pour diverses affections de santé.
Hypha Labs, Inc. (OTC PINK:DIGP) hat seinen Namen von Digipath, Inc. geändert, um sich auf die Herstellung von aktiven Inhaltsstoffen aus funktionalen Pilzen wie Psilocybin mittels innovativer Bioreaktor-Technologie zu konzentrieren. Das Unternehmen strebt an, reine, konsistente und messbare Dosierungen dieser Inhaltsstoffe für den Verbraucher- und kommerziellen Gebrauch anzubieten. Mit einem abonnementbasierten Modell plant Hypha Labs, die Produktion von funktionalen Pilzen zu revolutionieren und den wachsenden Markt für psychedelische und funktionale Pilze als potenzielle Behandlungen für verschiedene Gesundheitszustände zu erschließen.
Positive
None.
Negative
None.
LAS VEGAS, NV / ACCESSWIRE / April 22, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP) has announced that it has changed its name from Digipath, Inc. after the sale of its cannabis lab assets. In a change of direction, it has developed cutting edge technology focused on revolutionary methods of producing the active ingredients found in functional mushrooms such as psilocybin using its patent-pending bioreactor design. Its bioreactors will be available for both consumer and commercial large-scale applications. The technology produces pure, consistent, and measurable doses of the active ingredients in an easy to digest form from functional mushrooms such as Psilocybin and Lion's Main using its unique bioreactor technologies for home and commercial use.
We will be providing a wide variety of Mycelium varietals for use in the Hypha Labs' bioreactor which allows the production of useable active ingredients in 8-10 days versus traditional methods which require the actual growing of mushrooms in a substrate and then a complicated extraction method with variable dosing and side-effects taking up to 10 weeks. We plan on offering these ingredients on a subscription basis to use in our proprietary bioreactors.
Psychedelic and Functional Mushrooms, The Next Big Thing
Just as the landscape changed for cannabis, it is changing for functional mushrooms especially Psilocybin. There are currently over 100 clinical trials underway that are showing great promise in helping people suffering from anxiety, depression and PTSD, and other functional mushrooms are being studied for diabetes and memory. Hypha Labs, Inc, has developed technology that will allow consumers to grow the beneficial active ingredients in function mushrooms in the comfort of their own homes in 7-10 days not months to grow mushrooms. The results for consumers and commercial users are consistent, measurable and side-effect free.
The company has developed revolutionary cutting-edge Patent-Pending technology focused on new methods of producing the active ingredients found in functional mushrooms such as psilocybin using its patent pending bioreactor design. The Company has positioned itself to play an important role in the burgeoning Functional Mushroom industry in addition to be a disruptive force in the psilocybin space which is quickly manifesting into a similar pattern that was seen in the Cannabis Industry both from a medical and recreational usage with several states and cities have now decriminalized it use. Visit us at HyphaLabs.com.
What is the new name of Digipath, Inc. after the sale of its cannabis lab assets?
The new name of Digipath, Inc. after the sale of its cannabis lab assets is Hypha Labs, Inc.
What technology is Hypha Labs focusing on to produce active ingredients from functional mushrooms such as psilocybin?
Hypha Labs is using patent-pending bioreactor design to produce pure, consistent, and measurable doses of active ingredients from functional mushrooms like psilocybin.
What is the advantage of using Hypha Labs' bioreactor technology for producing active ingredients from functional mushrooms?
Hypha Labs' bioreactor technology allows for the production of usable active ingredients in 8-10 days, compared to traditional methods that may take up to 10 weeks.
What are some potential benefits of functional mushrooms like psilocybin according to Hypha Labs?
Hypha Labs mentions that functional mushrooms like psilocybin have shown promise in clinical trials for helping people with anxiety, depression, PTSD, diabetes, and memory.
Where will Hypha Labs be presenting in May 2024?
Hypha Labs will be presenting at the Planet MicroCap Showcase in Las Vegas on Wednesday, May 1, 2024, at 3 PM.
